By comparing chromatin accessibility (Formaldehyde-Assisted Isolation of Regulatory Elements (FAIRE)-seq) and AR chromatin binding profiles (Chromatin Immunoprecipitation (ChIP)-seq) in primary versus ADT-resistant tumors, we identified a distinct gene set that enables stratification of patients with prostate cancer on outcome. This evidence concerns the gene AR and prostate carcinoma.